Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Rennova Health's annualized net income for the quarter that ended in Dec. 2023 was $-37.06 Mil. Rennova Health's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $-32.45 Mil. Therefore, Rennova Health's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was N/A%.
The historical rank and industry rank for Rennova Health's Return-on-Tangible-Equity or its related term are showing as below:
RNVA's Return-on-Tangible-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -0.605 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Rennova Health (OTCPK:RNVA) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Rennova Health Return-on-Tangible-Equity Related Terms
Rennova Health Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Rennova Health's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNVA vs ISPC, CNTGF, NSTM: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Rennova Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rennova Health Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rennova Health's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Rennova Health's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2023) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Rennova Health (RNVA) has a Return-on-Tangible-Equity of 0.00% as of Dec. 2023. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Rennova Health and its competitors.
Is Rennova Health's Return-on-Tangible-Equity too high?
Rennova Health's current Return-on-Tangible-Equity is 0.00%. Overall, Rennova Health has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Rennova Health's Return-on-Tangible-Equity compare to ISPC and CNTGF?
Rennova Health's Return-on-Tangible-Equity of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Rennova Health and its competitors. Rennova Health's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rennova Health stock overvalued right now?
Rennova Health (RNVA) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Rennova Health's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Rennova Health (RNVA), the current Return-on-Tangible-Equity is 0.00% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rennova Health Inc is a vertically integrated provider of healthcare-related products and services. The company operates through a single business segment namely the Hospital operations segment reflects the purchase of the hospital assets. Geographically, the activities are carried out throughout the region of the United States.
12GF Score
Get the complete analysis for RNVA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNVA has been successfully added to your 
